Determination of T Cell Responses in Thai Systemic Sclerosis Patients

Objectives This study is aimed at determining the role of T cells by assessing the numbers of IFN-γ- and IL-2-secreting T cells following stimulation with peptides derived from DNA topoisomerase-I protein in Thai SSc patients. Methods Fifty Thai SSc patients and 50 healthy controls (HC) joined this study. IFN-γ and IL-2 levels upon stimulation of T cells with 6 peptides derived from DNA topoisomerase-I protein were determined. Anti-nuclear antibodies (ANA) and anti-Scl-70 antibodies were determined by using the ELISA method. Results In SSc patients, we detected a significantly higher number of IFN-γ- and IL-2-secreting CD8+ T cells than IFN-γ- and IL-2-secreting CD4+ T cells after stimulation with pooled peptides derived from DNA topoisomerase-I protein. A similar percentage of CD4+IL-2+, CD4+IFN-γ+, and CD8+IL-2+ were detected following stimulation with DNA topoisomerase-I protein -in SSc patients with anti-Scl-70 antibody (SSc/anti-Scl-70+) and those without. In contrast, the amount of CD8+IFN-γ+ cells was significantly higher in SSc/anti-Scl-70+ than those without. Stimulation with individual peptides showed that CSLRVEHINLHPELD (sPep3; 15 amino acids; position 505-519 of DNA topoisomerase-I protein) was the optimal epitope that induced T cells secreting the highest levels of IFN-γ and IL-2. A higher percentage of IFN-γ+CD4+ T cells was detected in SSc/anti-Scl-70+ than those without the following stimulation with peptides 2 (amino acid position 475-486 [RAVALYFIDKLA] of protein DNA topoisomerase). Conclusion The results from this study emphasize the critical role of DNA topoisomerase-I peptides on the activation of T cells in SSc patients. The findings provide a better understanding of SSc's immunopathogenesis and may lead to the development of diagnostic tools and specific treatments for SSc in the future.

[1]  L. Kanz,et al.  Invariant natural killer T cells are functionally impaired in patients with systemic sclerosis , 2019, Arthritis Research & Therapy.

[2]  H. Mariz,et al.  Different profile of cytokine production in patients with systemic sclerosis and association with clinical manifestations. , 2018, Immunology letters.

[3]  P. Puthavathana,et al.  H5N1 NS genomic segment distinctly governs the influenza virus infectivity and cytokine induction in monocytic cells. , 2018, Asian Pacific journal of allergy and immunology.

[4]  Xiaolei Tang,et al.  Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein. , 2017, Journal of visualized experiments : JoVE.

[5]  M. Kopeć-Mędrek,et al.  Systemic sclerosis sine scleroderma. , 2017, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[6]  Qing-Rong Liu,et al.  Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma , 2016, Arthritis Research & Therapy.

[7]  M. Pereira,et al.  Interferons and systemic sclerosis: correlation between interferon gamma and interferon-lambda 1 (IL-29) , 2015, Autoimmunity.

[8]  Jane Worthington,et al.  Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility , 2012, Annals of the rheumatic diseases.

[9]  T. Medsger,et al.  Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis. , 2013, Arthritis and rheumatism.

[10]  S. Pendergrass,et al.  Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension. , 2011, Arthritis and rheumatism.

[11]  P. Szodoray,et al.  Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneous systemic sclerosis , 2011, Scandinavian journal of rheumatology.

[12]  L. Michel,et al.  Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. , 2010, Autoimmunity reviews.

[13]  M. Mayes,et al.  Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations , 2009, Arthritis research & therapy.

[14]  R. Lafyatis,et al.  The Pronounced Th17 Profile in Systemic Sclerosis (SSc) Together with Intracellular Expression of TGFβ and IFNγ Distinguishes SSc Phenotypes , 2009, PloS one.

[15]  Rajiv Khanna,et al.  Preferential binding of unusually long peptides to MHC class I and its influence on the selection of target peptides for T cell recognition. , 2008, Molecular immunology.

[16]  A. Scarpa,et al.  Association of polymorphisms in the IL1B and IL2 genes with susceptibility and severity of systemic sclerosis. , 2007, The Journal of rheumatology.

[17]  T. Medsger,et al.  T cell lines from systemic sclerosis patients and healthy controls recognize multiple epitopes on DNA topoisomerase I. , 2006, Journal of autoimmunity.

[18]  M. Probst-Kepper,et al.  Conformational Restraints and Flexibility of 14-Meric Peptides in Complex with HLA-B*35011 , 2004, The Journal of Immunology.

[19]  K. Esposito,et al.  Peripheral Blood T Lymphocytes from Systemic Sclerosis Patients Show Both Th1 and Th2 Activation , 2001, Journal of Clinical Immunology.

[20]  M. Kaplan,et al.  Comprehensive mapping of HLA‐A*0201–restricted CD8 T‐cell epitopes on PDC‐E2 in primary biliary cirrhosis , 2002, Hepatology.

[21]  R. Steinman,et al.  Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells. , 2002, The Journal of infectious diseases.

[22]  M. Hasegawa,et al.  Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. , 2001, Rheumatology.

[23]  T. Mimori,et al.  Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. , 2000, Arthritis and rheumatism.

[24]  R. Scorza,et al.  Increased interferon‐gamma (IFN‐γ) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud's phenomenon , 1999, Clinical and experimental immunology.

[25]  F. Arnett,et al.  Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. , 1999, Arthritis and rheumatism.

[26]  K. Wiesmüller,et al.  Peptide length preferences for rat and mouse MHC class I molecules using random peptide libraries , 1998, European journal of immunology.

[27]  K. Welsh,et al.  HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients. , 1998, British journal of rheumatology.

[28]  R. Wise,et al.  Skewing of the CDS + T-cell repertoire in the lungs of patients with systemic sclerosis , 1996 .

[29]  T. Medsger,et al.  T and B cell collaboration is essential for the autoantibody response to DNA topoisomerase I in systemic sclerosis. , 1995, Journal of immunology.

[30]  T. Medsger,et al.  T cell proliferative response induced by DNA topoisomerase I in patients with systemic sclerosis and healthy donors. , 1995, The Journal of clinical investigation.

[31]  A Sette,et al.  Naturally processed peptides longer than nine amino acid residues bind to the class I MHC molecule HLA-A2.1 with high affinity and in different conformations. , 1994, Journal of immunology.

[32]  A. Silman,et al.  Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. , 1993, The Journal of rheumatology.

[33]  T. Whiteside,et al.  Cytokine production and serum levels in systemic sclerosis. , 1992, Clinical immunology and immunopathology.

[34]  P. Haslam,et al.  In vivo levels and in vitro production of interferon‐gamma in fibrosing interstitial lung diseases , 1992, Clinical and experimental immunology.

[35]  F. Wigley,et al.  Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. , 1992, Arthritis and rheumatism.

[36]  F. Wigley,et al.  Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. , 1992, Arthritis and rheumatism.

[37]  M. Kahaleh,et al.  Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration. , 1989, Annals of internal medicine.

[38]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.

[39]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[40]  Hugh Gordon,et al.  Scleroderma , 1937 .